

TO: **Mail Stop 8**  
**Director of the U.S. Patent and Trademark Office**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**REPORT ON THE  
 FILING OR DETERMINATION OF AN  
 ACTION REGARDING A PATENT OR  
 TRADEMARK**

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been  
 filed in the U.S. District Court Eastern District of Tennessee, Knoxville Division on the following

☒ Trademarks or ☐ Patents. ( ☐ the patent action involves 35 U.S.C. § 292.):

DOCKET NO. 3:11-cv-14	DATE FILED 01/11/2011	U.S. DISTRICT COURT Eastern District of Tennessee, Knoxville Division
PLAINTIFF  Bailey Sales Corporation		DEFENDANT  Northern Tool and Equipment Company, Inc
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 2020293	December 3, 1996	Bailey
2 2461099	June 19, 2001	Bailey
3 3586804	March 10, 2009	Bailey
4 3132303	August 22, 2006	Bailey
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading		
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK	
1			
2			
3			
4			
5			

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT  Agreed Order of Dismissal signed by Judge Varlan on 8/18/11
---

CLERK Patricia L. McNutt	(BY) DEPUTY CLERK A. Foster	DATE 8/18/11
-----------------------------	--------------------------------	-----------------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director  
 Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy



US006403649B1

**(12) United States Patent**  
**Woodward et al.****(10) Patent No.: US 6,403,649 B1**  
**(45) Date of Patent: \*Jun. 11, 2002****(54) NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS****(75) Inventors:** David F. Woodward, El Toro; Steven W. Andrews, Rancho Santa Marguerita; Robert M. Burk, Irvine; Michael E. Garst, Newport Beach, all of CA (US)**(73) Assignee:** Allergan Sales, Inc., Irvine, CA (US)**(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

**(21) Appl. No.:** 09/519,834**(22) Filed:** Mar. 6, 2000**Related U.S. Application Data****(60)** Continuation of application No. 08/876,937, filed on Jun. 16, 1997, which is a continuation of application No. 08/605,567, filed on Feb. 22, 1996, now Pat. No. 5,688,819, which is a continuation-in-part of application No. 08/371,339, filed on Jan. 11, 1995, now Pat. No. 5,607,978, which is a continuation of application No. 08/154,244, filed on Nov. 18, 1993, now abandoned, which is a division of application No. 07/948,056, filed on Sep. 21, 1992, now Pat. No. 5,352,708.**(51) Int. Cl.<sup>7</sup>** ..... A61K 31/135**(52) U.S. Cl.** ..... 514/646; 564/171; 564/189**(58) Field of Search** ..... 514/530, 546, 514/548, 555, 570, 913, 646; 560/53, 60, 255; 562/452, 465; 564/171, 189**(56) References Cited****U.S. PATENT DOCUMENTS**

4,055,602 A	10/1977	Nelson
4,097,489 A	6/1978	Bundy
4,128,713 A	12/1978	Schneider
4,131,738 A	12/1978	Smith
4,171,331 A	10/1979	Biddlecom et al.
4,183,870 A	1/1980	Caton et al.
4,444,788 A	4/1984	Skuballa et al.
4,599,353 A	7/1986	Bito
4,994,274 A	2/1991	Chan et al.
5,034,413 A	7/1991	Chan et al.
5,352,708 A	10/1994	Woodward et al.
5,414,016 A	5/1995	Skuballa et al.
5,510,383 A	4/1996	Bishop et al.
5,545,665 A	8/1996	Burk
5,587,391 A	12/1996	Burk
5,607,978 A	3/1997	Woodward et al.

**FOREIGN PATENT DOCUMENTS**

CA	2036386	1/1991
CS	271137	* 8/1990
DE	27 21 534	12/1977
EP	0 093 380	11/1983

EP	0 102 230	7/1984
EP	0 253 094	1/1988
EP	0 364 417	1/1989
EP	0 453 127	10/1991
FR	2 312 240	12/1976
FR	2 386 523	11/1978
FR	2 402 644	3/1979
LU	68 940	2/1974
WO	90/02553	3/1990
WO	92/08465	5/1992

**OTHER PUBLICATIONS**

Prostaglandins: vol. 13, No. 5, May 1977, Stoneham, MA, pp. 837-843, H.C. Arndt, "The Synthesis and Biological Activity of Prostaglandins Analogs Containing Spirocyclic Rings".

Tetrahedron: Vol. 32, 1976, Oxford GB, pp. 2747-2752, P. De Clercq et al., "Cyclopentanones-XVI. Prostaglandin Synthesis Involving Catalytic Hydrogenation of 2,3-Dialkyl-4-Hydroxy-2-Cyclopentenones".

Derwent Pub. Lts. London GB AN 71-57225 &amp; JPA, 46 030 830, Ono Pharmaceutical Co., Sep. 7, 1971.

Bito, L.Z., "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents", Biological Protection with Prostaglandins (Cohen, M.M., ed., Boca Raton, FL, CRC Press Inc., 1985, pp. 231-252.

Bito, L.Z., "Prostaglandins, Old Concepts and New Perspectives," Arch Oph., vol. 105, Aug. 1987 p. 1036-1039.

Starr, M.S., "Further Studies on the Effect of Prostaglandin on Intraocular Pressure in the Rabbit", Exp. Eye Res., (1971) 170-177.

Nilsson, Siv F.E., et al., "PGF<sub>2a</sub> Increases Uveoscleral Outflow", ARVO Abstract, p. 284, Invest. Ophthalmol. Vis. Sci. 28 (suppl) (1987).

Bito, L.Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents", Applied Pharmacology in the Medical Treatment of Glaucoma, pp. 477-505, 1984.

\* cited by examiner

Primary Examiner—Sreeni Padmanabhan

(74) Attorney, Agent, or Firm—Robert J. Baran; Martin A. Voet; Carlos A. Fisher

**(57) ABSTRACT**

The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

**3 Claims, No Drawings**